Houston, TX, USA, For Release: 8th September 2015. Algorics, a provider of clinical analytics solutions and software for the global life sciences industry, today announced that acuity, its analytics solution for risk based monitoring, has been adopted by Lexitas Pharma Services, Inc. The US Ophthalmology-focused CRO will leverage the acuity solution to bring together internal and external data sources in order to provide analytics dashboards and alerts to give the leadership team a real-time picture of key operational parameters and KRI (key risk indicators) and allow operational teams to more easily manage trial performance.
“As Lexitas grows we continue to look for innovative ways to improve efficiency without compromising the high quality and tailored services our clients count on. Implementing acuity will provide us with a timely and comprehensive view of how our portfolio of trials is performing, as well as enable us to manage individual trials in the most effective way,” said Chad Ice, President, Lexitas.
Nick Hargaden, President, Algorics said, “We are delighted that Lexitas has chosen acuity to provide centralized insights into the clinical trials they manage, thus driving operational effectiveness and resource savings.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.